For VCs & Investors
A physician (MD) and biomedical engineer (BME) read on every deal — grounded in a proprietary multi-source substrate, with every material factual claim cited to a public source. License Vantage as your fund's diligence bench, or run a single deal to see the work first.
We don't forecast outcomes — we make knowable risk legible. The read a senior physician and biomedical engineer would run on a deal, delivered faster, cheaper, and more comprehensively than your realistic alternative — an associate, a banker, or a generic LLM that fabricates — with every material factual claim traced to a public source.
Batch Pipeline Screening
Watch Vantage transform an unscored pipeline into ranked, actionable intelligence
| Company | Score | Status |
|---|
Why Vantage
Get institutional-grade risk assessment without institution-grade timelines or costs
What We Find
Six headline categories within our full 20-category framework — the dimensions where early-stage medtech deals most often break.
Risk categories scored per deal
Outcome-labeled companies in cohort substrate
Traced to a public source — we never fabricate
Differentiator analysis with effect-size disclosure
Engineering gaps and design flaws typically invisible to external investors. We validate scalability assumptions.
Study design flaws, endpoint selection bias, and generalizability limits that regulators will challenge.
Predicate strategies and pathway assumptions. A misjudged predicate or pathway can add many months and material cost before a device reaches market.
Patent scope, freedom-to-operate risks, and competitive landscape. Defensive patent strategies matter early.
Cross-functional execution risk assessment. Technical gaps in regulatory, clinical, and manufacturing leadership.
Reimbursement pathways, payer concentration risk, and pricing sustainability validated through federal data.
Licensing & Evaluations
Most funds license Vantage as an always-on diligence resource across their deal flow. Prefer to see the work first? Run one deal — the fee credits toward a license if you convert.
Priced to how many deals you run — a fraction of the $150–250K associate you can't hire. Every material factual claim cited to a public source; we never fabricate.
Scout
Fund · Most chosen
Platform
Enterprise — from $150,000 / year. For high-volume funds and PE portfolios: a scoped annual report allowance, full portfolio monitoring, and post-close tracking, scoped to your portfolio. See portfolio & PE →
The à-la-carte option
A low-commitment proof of capability before you license. A single evaluation's fee credits toward a license if you convert.
Running diligence across a whole portfolio or fund? The Vantage License covers unlimited screening plus your annual diligence reports. Talk to Arvind, MD →
A single missed clinical, regulatory, or technical risk can cost far more than the diligence that would have surfaced it.
Investment Timeline
Your licensed diligence bench across sourcing, screening, diligence report, and portfolio monitoring
Portfolio screening to identify high-risk categories early
Quick Screen on top 10 for rapid triage
Diligence Report with MD debrief on finalists
Risk-stratified report and recommendations
Milestone tracking and portfolio risk management
Methodology in public
Before you trust an investor-grade read, see the framework run on companies whose outcomes are now public. No private claims, no unnamed founders, no rewrites.
Polyethylene packaging defect, roughly 200,000 implants recalled, Chapter 11 in 2024. We walk the technology and supply-chain signals that were public years earlier.
Source: FDA recall notices & 2024 Chapter 11 filings (D. Del.) Read the retrospective →First FDA-cleared prescription digital therapeutic, $1.6B SPAC valuation (2021), bankruptcy by 2023. The coverage and prescribing-economics gaps were knowable pre-deal.
Source: 2021 SPAC merger & 2023 Chapter 11 filings (SEC / D. Del.) Read the retrospective →An FDA warning letter forced a category change from wellness to medical device, halting US sales until a reclassified product cleared FDA. We trace the regulatory trigger from public filings predating the IPO.
Source: FDA warning letter (2021) & public SEC filings Read the retrospective →We don't publish unnamed-client testimonials. When a sponsor allows it, we'll cite them by name. Until then, our work is judged on the rigor and traceability of the methodology you can read end to end.
License Vantage for always-on screening and diligence reports across your fund — or run a single deal to see the work first. The evaluation fee credits toward a license.
20 clinical, regulatory, and technical questions every investor should ask — curated by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Download the ChecklistNo email required. No paywall.